October 09, 2026 02:53 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Bold and inventive’: Canadian poet Anne Carson wins 2026 Nobel Prize in Literature | ‘Attempt to destabilise world’s largest democracy’: 42 retired judges rally behind Gyanesh Kumar over ‘vote chori’ row | ‘Vote chor, gaddi chod’: Dhruv Rathee, Prakash Raj join Bengaluru protest against Gyanesh Kumar | India condemns Houthi attacks on Saudi airports, calls targeting of civilian infrastructure unacceptable | Dalal Street bloodbath: Investors lose Rs. 8 lakh crore as Sensex crashes over 1,000 points | Amazon layoffs hit India, US and UK: Fresh job cuts rock e-commerce giant amid festive shopping season | Bollywood mourns Nana Patekar: Anupam Kher, Akshay Kumar, Jr NTR, Suniel Shetty pay emotional tributes | ‘He was never wavering while expressing his opinions’: PM Modi mourns Nana Patekar | Nana Patekar dies at 75: Veteran actor suffers cardiac arrest at Goa home | RBI shocks borrowers with first repo rate hike since 2023; rates raised to 5.50%
Johnson & Johnson
Pixabay

Fight against COVID-19: Johnson & Johnson's vaccine shows strong immune response

| @indiablooms | Sep 26, 2020, at 02:21 pm

New Brunswick: US pharmaceutical major  Johnson & Johnson's potential COVID-19 vaccine has shown development of a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated.

The company published an interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) on Friday.

" Immune responses were similar across the age groups studied, including older adults," the company said in a statement.

"The ongoing Phase 1/2a clinical trial is designed to study the safety and immunogenicity of two dose levels of the Janssen COVID-19 vaccine, and as single and two-dose schedules," the company said.

The interim analysis showed that a single dose induced a robust immune response and was generally well-tolerated.  

" These data are consistent with preclinical studies, published in the scientific journal Nature, which showed that a single dose of the vaccine successfully prevented subsequent infection and provided complete protection in the lungs of nonhuman primates," read the statement.

"Based on these findings, the single dose of the Janssen COVID-19 vaccine candidate of 5x1010 virus particles (vp) has been selected for further evaluation in the Phase 3 ENSEMBLE clinical trial," the company said.

The company also plans on running a Phase 3 clinical trial of a two-dose regimen of JNJ-78436735 versus placebo later this year.

The full set of results will be published once the complete Phase 1/2a trial data are available.
" The Janssen COVID-19 vaccine candidate elicited strong antibody responses, strong T cell responses, and a Th1 response, believed to be protective against the risk of vaccine-associated enhanced respiratory disease," the company said.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.